Market Overview:
The global DNA diagnostics/testing market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The market growth is attributed to the increasing demand for personalized medicine, rising prevalence of genetic disorders, and technological advancements in DNA diagnostics/testing. Based on type, the PCR-based diagnostics segment is expected to account for the largest share of the global DNA diagnostics/testing market in 2018. This segment is mainly driven by the increasing demand for molecular diagnostic tests and growing use of PCR technology in various applications such as oncology diagnosis & histopathology, identity diagnosis & forensics, pharmacogenomics diagnostic testing & drug metabolism etc. Based on application, the oncology diagnostics & histopathology segment accounted for the largest share of the global DNA diagnostics/testing market in 2017 and this trend is projected to continue during forecast period.
Product Definition:
DNA diagnostics is a field of medicine that uses DNA analysis to diagnose and treat diseases. This can include identifying the genes that are associated with a particular disease, or looking for mutations in DNA that may be associated with cancer.
PCR Based Diagnostics:
Polymerase Chain Reaction (PCR) is a technique that uses a DNA-copying machine called the polymerase chain reaction to make many copies of an accurate section of DNA. The process can be used to detect and quantify genetic materials such asDNA, RNA, chromatin, and genomic DNA. PCR based diagnostic tests are widely applied in medical diagnosis due to its high sensitivity & specificity in detecting various diseases caused by pathogens or bacteria including H1N1 Swine flu virus.
NGS DNA Diagnosis:
NGS DNA diagnosis is a new and emerging field of genetic investigation that allows the examination of DNA for specific characteristics. It helps in the rapid and precise detection of changes or mutations in the genome. The technology has been used to conduct whole-genome sequencing, which is further used for identifying diseases, determining drug resistance patterns, and tracing back family trees.
Application Insights:
Oncology diagnostics & histopathology segment dominated the global DNA diagnostics/testing market in 2017. This is owing to factors such as presence of well-established and widely adopted diagnostic procedures for oncology, growing prevalence of cancer across the globe, and increasing investments by companies in R&D pertaining to genetic causes of cancer. For instance, in September 2016 it was announced that a joint venture between Amgen and Mitsubishi would invest around USD 250 million over 5 years towards development of novel genomic solutions for oncology. Similarly, other prominent players have also made significant investments towards development of new products or improved versions existing ones pertaining to oncological diagnosis.
ID Diagnostics & forensics segment is expected to grow at lucrative CAGR during the forecast period owing to increase in demand for rapid identification through forensic science services after major criminal incidents such as terrorist attacks or mass shootings involving human remains with potential evidence related identity information (e.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to presence of well-established healthcare infrastructure, high adoption rate of advanced technologies, and local presence of key players. Moreover, increasing prevalence of chronic diseases coupled with rising demand for personalized medicine is expected to drive the regional market over the forecast period.
Asia Pacific is estimated to witness lucrative growth during the forecast period owing to rise in government initiatives pertaining DNA testing services and introduction of new diagnostic techniques such as NGS that are not available in Western countries. In addition, growing penetration rates for these tests due to increase awareness about early diagnosis are anticipated to boost revenue generation capacity over projected time frame 8). Furthermore, availability at low cost makes this region a preferred destination for outsourcing clinical trials involving genetic analysis 9). Rise in number & scope cancer diagnostics & research studies being conducted within Asian countries also supports regional growth 10) ).
Growth Factors:
- Increasing demand for personalized medicine
- Rising prevalence of genetic disorders
- Technological advancements in DNA sequencing and analysis
- Growing public awareness about the benefits of DNA testing
- Increasing demand for precision medicine
Scope Of The Report
Report Attributes
Report Details
Report Title
DNA Diagnostics/Testing Market Research Report
By Type
PCR Based Diagnostics, NGS DNA Diagnosis, In-situ Hybridization Diagnostics, Micro-arrays Based Diagnostics
By Application
Oncology Diagnostics & Histopathology, Identity Diagnostics & Forensics, Pharmacogenomics Diagnostic Testing & Drug Metabolism
By Companies
Abbott Laboratories, Affymetrix Inc., Agilent Technologies Inc, Applied Biosystems Group, Illumina Inc., Cepheid Inc., Hologic, Bio-Rad Laboratories, Dako, Abbott, Roche Diagnostics, Beckman Coulter Inc., Siemens Healthcare
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
188
Number of Tables & Figures
132
Customization Available
Yes, the report can be customized as per your need.
Global DNA Diagnostics/Testing Market Report Segments:
The global DNA Diagnostics/Testing market is segmented on the basis of:
Types
PCR Based Diagnostics, NGS DNA Diagnosis, In-situ Hybridization Diagnostics, Micro-arrays Based Diagnostics
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Oncology Diagnostics & Histopathology, Identity Diagnostics & Forensics, Pharmacogenomics Diagnostic Testing & Drug Metabolism
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbott Laboratories
- Affymetrix Inc.
- Agilent Technologies Inc
- Applied Biosystems Group
- Illumina Inc.
- Cepheid Inc.
- Hologic
- Bio-Rad Laboratories
- Dako
- Abbott
- Roche Diagnostics
- Beckman Coulter Inc.
- Siemens Healthcare
Highlights of The DNA Diagnostics/Testing Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- PCR Based Diagnostics
- NGS DNA Diagnosis
- In-situ Hybridization Diagnostics
- Micro-arrays Based Diagnostics
- By Application:
- Oncology Diagnostics & Histopathology
- Identity Diagnostics & Forensics
- Pharmacogenomics Diagnostic Testing & Drug Metabolism
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the DNA Diagnostics/Testing Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
DNA diagnostics/testing is a process that uses DNA to identify the cause of a disease or illness. This can be done through tests that look for specific genetic markers in the DNA of cells.
Some of the major companies in the dna diagnostics/testing market are Abbott Laboratories, Affymetrix Inc., Agilent Technologies Inc, Applied Biosystems Group, Illumina Inc., Cepheid Inc., Hologic, Bio-Rad Laboratories, Dako, Abbott, Roche Diagnostics, Beckman Coulter Inc., Siemens Healthcare.
The dna diagnostics/testing market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 DNA Diagnostics/Testing Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 DNA Diagnostics/Testing Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 DNA Diagnostics/Testing Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the DNA Diagnostics/Testing Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global DNA Diagnostics/Testing Market Size & Forecast, 2020-2028
4.5.1 DNA Diagnostics/Testing Market Size and Y-o-Y Growth
4.5.2 DNA Diagnostics/Testing Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 PCR Based Diagnostics
5.2.2 NGS DNA Diagnosis
5.2.3 In-situ Hybridization Diagnostics
5.2.4 Micro-arrays Based Diagnostics
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Oncology Diagnostics & Histopathology
6.2.2 Identity Diagnostics & Forensics
6.2.3 Pharmacogenomics Diagnostic Testing & Drug Metabolism
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global DNA Diagnostics/Testing Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 DNA Diagnostics/Testing Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 PCR Based Diagnostics
9.6.2 NGS DNA Diagnosis
9.6.3 In-situ Hybridization Diagnostics
9.6.4 Micro-arrays Based Diagnostics
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Oncology Diagnostics & Histopathology
9.10.2 Identity Diagnostics & Forensics
9.10.3 Pharmacogenomics Diagnostic Testing & Drug Metabolism
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 PCR Based Diagnostics
10.6.2 NGS DNA Diagnosis
10.6.3 In-situ Hybridization Diagnostics
10.6.4 Micro-arrays Based Diagnostics
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Oncology Diagnostics & Histopathology
10.10.2 Identity Diagnostics & Forensics
10.10.3 Pharmacogenomics Diagnostic Testing & Drug Metabolism
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 PCR Based Diagnostics
11.6.2 NGS DNA Diagnosis
11.6.3 In-situ Hybridization Diagnostics
11.6.4 Micro-arrays Based Diagnostics
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Oncology Diagnostics & Histopathology
11.10.2 Identity Diagnostics & Forensics
11.10.3 Pharmacogenomics Diagnostic Testing & Drug Metabolism
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 PCR Based Diagnostics
12.6.2 NGS DNA Diagnosis
12.6.3 In-situ Hybridization Diagnostics
12.6.4 Micro-arrays Based Diagnostics
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Oncology Diagnostics & Histopathology
12.10.2 Identity Diagnostics & Forensics
12.10.3 Pharmacogenomics Diagnostic Testing & Drug Metabolism
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 PCR Based Diagnostics
13.6.2 NGS DNA Diagnosis
13.6.3 In-situ Hybridization Diagnostics
13.6.4 Micro-arrays Based Diagnostics
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Oncology Diagnostics & Histopathology
13.10.2 Identity Diagnostics & Forensics
13.10.3 Pharmacogenomics Diagnostic Testing & Drug Metabolism
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 DNA Diagnostics/Testing Market: Competitive Dashboard
14.2 Global DNA Diagnostics/Testing Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Abbott Laboratories
14.3.2 Affymetrix Inc.
14.3.3 Agilent Technologies Inc
14.3.4 Applied Biosystems Group
14.3.5 Illumina Inc.
14.3.6 Cepheid Inc.
14.3.7 Hologic
14.3.8 Bio-Rad Laboratories
14.3.9 Dako
14.3.10 Abbott
14.3.11 Roche Diagnostics
14.3.12 Beckman Coulter Inc.
14.3.13 Siemens Healthcare
